“What’s true is that many cancer treatments still start with surgery," she told The Associated Press in an interview. "So being really smart and attacking and developing new technology to make that first step better could really revolutionize how we are able to treat cancer for so many Americans."
In the case of Imagion's completed Phase 1 FIH study... "After a new breast cancer diagnosis, the patient is assessed for metastatic disease, initially by nodal staging. Ultrasound is limited to morphological assessment (node size and shape), is limited in the area that can be scanned, and is highly dependent on the experience of the operator. As a result, diagnostic sensitivity and specificity is highly variable and so whether there is a suspected presence of abnormal nodes or not, a patient will typically be required to have additional evaluation by biopsy and pathologic confirmation. Recently the breast cancer community has been making a push towards “de-escalation of axillary surgery”, i.e. reducing node removals and biopsies.
"Prabhakar, a former director of DARPA, said most federal research dollars are designed to go to university or government labs, while ARPA-H programs will search more broadly."
Many paths forward to assist in funding the Phase 2 study exist, this is one such possibility. GLTA Investors
IBX Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)